• 1
    Prorok PC, Hankey BF, Bundy BN. Concepts and problems in the evaluation of screening programmes. J Chronic Dis 1981; 37: 159171.
  • 2
    UK Trial of Early Detection of Breast Cancer Group. First results on mortality reduction in the UK Trial of Early Detection of Breast Cancer. Lancet 1988; 2: 4116.
  • 3
    Moss SM, Summerley ME, Thomas BT, Ellman R, Chamberlain JO. A case–control evaluation of the effect of breast cancer screening in the United Kingdom trial of early detection of breast cancer. J Epidemiol Community Health 1992; 46: 3624.
  • 4
    IARC working group on cervical cancer screening 1986. In Hakama M, Miller AB, Day NE, editors. Screening for cancer of the uterine cervix. IARC Scientific Publication No. 76 Lyon, France: IARC, 1996: 13342.
  • 5
    Ebeling K, Nischan P. Screening for lung cancer — results from a case–control study. Int J Cancer 1987; 40: 22930.
  • 6
    Berndt R, Nischan P, Ebeling K. Screening for lung cancer in the middle-aged. Int J Cancer 1990; 45: 22930.
  • 7
    Sobue T, Suzuki T, Naruke T. A case–control study for evaluating lung-cancer screening in Japan. Japanese Lung- Cancer-Screening Research Group. Int J Cancer 1992;50: 2307.
  • 8
    Moss S, Draper GJ, Hardcastle JD, Chamberlain J. Calculation of sample size of trials of screening for early diagnosis of disease. Int J Epidemiol 1987; 16: 1041110.
  • 9
    Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989; 8: 43140.
  • 10
    Day NE, Williams DR, Khaw KT. Breast cancer screening programmes: the development of a monitoring and evaluation system. Br J Cancer 1989; 59: 9548.
  • 11
    Duffy SW, Tabar L, Fagerberg G, Gad A, Grontoft O, South MC, Day NE. Breast screening, prognostic factors and survival — results from the Swedish two county study. Br J. Cancer 1991; 64: 113338.
  • 12
    Morrison AS. Intermediate determinants of mortality in the evaluation of screening. Int J Epidemiol 1991; 20: 64250.
  • 13
    Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, James PD, Mangham CM. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996; 348: 147277.
  • 14
    Mapp TJ, Hardcastle JD, Moss SM, Robinson MHE. Survival of patients with colorectal cancer diagnosed in a randomised controlled trial of faecal occult blood screening. Br J Surg 1999; 86: 128691.
  • 15
    Strauss GM. Lung cancer screening and randomized population trials. In: Dominioni L, Strauss G, editors. International Conference on Prevention and Early Diagnosis of Lung Cancer, Varese, Italy, Dec 9–10. 1998: 5797.
  • 16
    Parkin DM, Pisani P. Screening for lung cancer. In: Miller, AB editor. Advances in cancer screening. Boston: Kluwer Academic Publishers, 1996: 1218.
  • 17
    Wilde J. A 10 year follow-up of semi-annual screening for early detection of lung cancer in the Erfurt County, GDR. Eur Respir J 1989; 2: 65662.
  • 18
    Friedman GD, Collen MF, Fireman BH. Multiphasic Health Checkup Evaluation: a 16-year follow-up. J Chronic Dis 1986; 39: 45363.
  • 19
    Fontana RS, Sanderson DR, Woolner LB, Taylor WF, Miller WE, Muhm JR, Bernatz PE, Payne WS, Pairolero PC, Bergstralh EJ. Screening for lung cancer. A critique of the Mayo Lung Project. Cancer 1991;67: 115564.
  • 20
    Brett GZ. The value of lung cancer detection by six-monthly chest radiographs. Thorax 1968; 23: 41420.
  • 21
    Kubik A, Parkin DM, Khlat M, Erban J, Polak J, Adamec M. Lack of benefit from semi-annual screening for cancer of the lung: follow-up of a randomized controlled trial on a population of high risk males in Czechoslovakia. Int J Cancer 1990; 45: 2633.
  • 22
    Shapiro S, Venet W, Strax P, Venet L. Current results of the breast cancer screening randomized trial: The health insurance plan (HIP) of greater New York Study. In: Day NE, Miller AB, editors. Screening for breast cancer. UICC International Union Against Cancer. Toronto: Hans Huber Publications,. 1988: 315.
  • 23
    Tabar L, Fagerberg CJ, Gad A, Baldetorp L, Holmberg LH, Grontoft O, et al. Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the Breast Cancer Screening Working Group of the Swedish Board of Health and Welfare. Lancet 1985;1: 829– 32.
  • 24
    Tabar L, Fagerberg CJG, Day NE. Evaluation of the results. In: Day NE, Miller AB, editors. Screening for breast cancer. UICC International Union Against Cancer. Toronto: Hans Huber Publications, 1988: 3944.
  • 25
    Tabar L, Fagerberg G, Chen HH, Duffy SW, Smart CR, Gad A, Smith RA. Efficacy of breast cancer screening by age. Cancer 1995; 75: 250717.
  • 26
    Bjurstam N, Bjorneld L, Duffy SW, Smith TC, Cahlin E, Eriksson O, et al. The Gothenburg breast screening trial: first results on mortality, incidence, and mode of detection for women aged 39–49 years at randomization. Cancer 1997; 80: 20919.
  • 27
    Andersson I, Aspegren K, Janzon L, Landberg T, Lindholm K, Linell F, Ljungberg O, Ranstam J, Sigfusson B. Mammographic screening and mortality from breast cancer: the Malmo mammographic screening trial. BMJ 1988; 297: 9438.
  • 28
    Moss SM, Michel M, Patnick J, Johns L, Blanks R, Chamberlain J. Results from the NHS breast screening programme 1990-1993. J Med Screen 1995; 2: 18690.
  • 29
    Ernster VL, Barclay J. Increases in ductal carcinoma in situ (DCIS) of the breast in relation to mammography: a dilemma. J Natl Cancer Inst Monogr 1997; 22: 1516.
  • 30
    Smith DS, Catalona WJ, Herschman JD. Longitudinal screening for prostate cancer with prostate-specific antigen. JAMA 1996; 176: 130915.
  • 31
    Breslow N, Chen CW, Dhan G, Drury RAB, Franks LM, Gellei B, et al. Latent carcinoma of prostate at autopsy in seven areas. Int J Cancer 1977; 20: 6808.
  • 32
    Yatani R; Chigusa I; Akazaki K; Stemmermann GN; Welsh RA; Correa P. Geographic pathology of latent prostatic carcinoma. Int J Cancer 1982; 29: l611-6.
  • 33
    Brendler CB. Characteristics of prostate cancer found with early detection regimens. Urology 1995; 46: 716.
  • 34
    Smith DS, Catalona WJ. The nature of prostate cancer detected through prostate specific antigen based screening. J. Urol 1994; 152: 17326.
  • 35
    Chambelain J, Melia J, Moss S, Brown J. Report prepared for the Health Technology Assessment panel of the NHS Executive on the diagnosis, management, treatment and costs of prostate cancer in England and Wales. Br J Urol 1997;(Suppl 3): 132.
  • 36
    Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA 1995; 273: 54852.
  • 37
    Lu-Yao GL, Greenberg ER. Changes in prostate cancer incidence and treatment in USA. Lancet 1994; 343: 2514.
  • 38
    Hoeksema MJ, Law C. Cancer mortality rates fall: a turning point for the nation. J Natl Cancer Inst 1996; 88: 17067.
  • 39
    Prorok PC, Byar DP, Smart C, et al. Evaluation of screening for prostate, lung and colorectal cancer: the PLC trial. In: Millar AB, Chamberlain J, Day NE, Prorok PC, editors. Cancer Screening. Cambridge: Cambridge University Press, 1991: 30020.
  • 40
    Auvinen A, Rietbergen JB, Denis LJ, Schroder FH, Prorok PC. Prospective evaluation plan for randomised trials of prostate cancer screening. The International Prostate Cancer Screening Trial Evaluation Group. J Med Screen 1996;3: 97104.
  • 41
    Coldman AJ, Fryer CJ, Elwood JM, Sonley MJ. Neuroblastoma: influence of age at diagnosis, stage, tumor site, and sex on prognosis. Cancer 1980; 46: 1896901.
  • 42
    Sawada T, Kidowaki T, Sakamoto I, Hashida T, Matsumura T, Nakagawa M, Kusunoki T. Neuroblastoma. Mass screening for early detection and its prognosis. Cancer 1984;53: 27315.
  • 43
    Bessho F. Effects of mass screening on age-specific incidence of neuroblastoma. Int J Cancer 1996; 67: 5202.
  • 44
    Yamamoto K, Hayashi Y, Hanada R, Kihochi A, Ichikawa M, Tanimura M, Yoshioka S. Mass screening and age-specific incidence of neuroblastoma in Saitani Prefecture, Japan. J Clin Oncol 1995; 13: 20338.
  • 45
    Hayashi Y, Hanada R, Yamamoto K. Biology of neuroblastomas in Japan found by screening. Am J Pediatr Hematol Oncol 1992; 14(4): 3427.
  • 46
    Naito M, Iwafuchi M, Ohsawa Y, Uchiyama M, Hirota M, Matsuda Y, Iinuma Y. Flow cytometric DNA analysis of neuroblastoma: prognostic significance of DNA ploidy in unfavorable group. J Pediatr Surg 1991; 26: 8347.
  • 47
    Brodeur GM, Hayes FA, Green AA, Casper JT, Wasson J, Wallach S, Seeger RC. Consistent N-myc copy number in simultaneous or consecutive neuroblastoma samples from sixty individual patients. Cancer Res 1987; 47: 424853.
  • 48
    Woods WG, Tuchman M, Robinson LL, Bernstein M, Leclerc J-M, Brisson LC, et al. Screening for neuroblastoma is ineffective in reducing the incidence of infavourable advanced stage disease in older children. Eur J Cancer 1997; 33: 210612.
  • 49
    Yamamoto K, Hanada R, Ichikawa M, Aihara T, Oguma E, Moriteni T, Shinanuchi Y, Tanimura M, Hayashi Y. Spontaneous regression of localised neuroblastoma detected by mass screening. J Clin Oncol 1998; 16: 12659.
  • 50
    Dominioni L. Stage I NSCLC: analysis of survival. In: Dominioni L, Strauss G, editors. International Conference on Prevention and Early Diagnosis of Lung Cancer; 1998 Dec 9–10; Varese, Italy. Varese: University of Insubria, 1998: 89.
  • 51
    McFarlane MJ, Feinstein AR, Wells CK, Chan CK. The “epidemiologic necropsy”. Unexpected detections, demographic selections, and changing rates of lung cancer. JAMA 1987;258: 331––8.
  • 52
    Chan CK, Wells CK, McFarlane MJ, Feinstein AR. More lung cancer but better survival. Implications of secular trends in “necropsy surprise” rates. Chest 1989;96: 2916.
  • 53
    Weiss W. Implications of tumor growth rate for the natural history of lung cancer. J Occup Med 1984; 26: 34552.
  • 54
    Walter SD, Kubik A, Parkin DM, Reissigova J, Adamec M, Khlat M. The natural history of lung cancer estimated from the results of a randomized trial of screening. Cancer Causes Control 1992; 3: 11523.
  • 55
    Eddy D. Screening for lung cancer. Ann Intern Med 1989; 111: 2327.